Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia 1

Interventions

Cyclophosphamide 143fludarabine phosphate 130Busulfan 109Tacrolimus 94fludarabine 93Mycophenolic Acid 90Whole-Body Irradiation 84Peripheral Blood Stem Cell Transplantation 81Imatinib Mesylate 69Antilymphocyte Serum 67Cyclosporine 66Azacitidine 64Cytarabine 63Methotrexate 60Melphalan 60Filgrastim 50Granulocyte Colony-Stimulating Factor 40Decitabine 40Thiotepa 38thymoglobulin 34Stem Cell Transplantation 34Dasatinib 34Radiotherapy 33nilotinib 31ruxolitinib 28Cord Blood Stem Cell Transplantation 28venetoclax 26Clofarabine 25Specimen Handling 24Methylprednisolone 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × siplizumab × Myeloid × Clear all
NCT00113646 2018-03-16

Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

Massachusetts General Hospital

Phase 2 Terminated
14 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡